The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation
- PMID: 16738250
- PMCID: PMC2684824
- DOI: 10.1523/JNEUROSCI.0959-06.2006
The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation
Abstract
First-degree family history of sporadic Alzheimer disease (AD) and the apolipoprotein E epsilon4 (APOE4) are risk factors for developing AD. Although the role of APOE4 in AD pathogenesis has been well studied, family history remains a rarely studied and poorly understood risk factor. Both putatively cause early brain changes before symptomatic disease, but the relative contribution of each to brain function is unknown. We examined 68 middle-aged participants with a parent diagnosed with AD [family history (+FH)] and 64 age- and education-matched controls without a first-degree family history of any dementia [no family history (-FH)]. All underwent cognitive testing, APOE genotyping, and a functional magnetic resonance imaging encoding task that required discrimination of novel items from previously learned items. A 2 x 2 factorial ANOVA (presence/absence of parental family history and presence/absence of the APOE4) was used to detect group effects. A greater response to novel items was detected in the mesial temporal lobe and fusiform gyrus bilaterally among persons without a first-degree family history of AD. In hippocampal areas, the -FH +epsilon4 group exhibited the greatest signal change, and the +FH +epsilon4 group exhibited the least. These findings indicate that FH of AD is an important predictor of hippocampal activation during encoding and that FH may modulate the effect of APOE4 in these middle-aged adults, suggesting that an as yet unspecified factor embodied in first-degree family history of AD is influencing the expression of APOE4 on brain function.
Figures
References
-
- Baxter LC, Caselli RJ, Johnson SC, Reiman E, Osborne D (2003). Apolipoprotein E epsilon 4 affects new learning in cognitively normal individuals at risk for Alzheimer's disease. Neurobiol Aging 24:947–952. - PubMed
-
- Bernardini S, Bellincampi L, Ballerini S, Federici G, Iori R, Trequattrini A, Ciappi F, Baldinetti F, Bossu P, Caltagirone C, Spalletta G (2005). Glutathione S-transferase P1 *C allelic variant increases susceptibility for late-onset Alzheimer disease: association study and relationship with apolipoprotein E epsilon4 allele. Clin Chem 51:944–951. - PubMed
-
- Bertram L, Hiltunen M, Parkinson M, Ingelsson M, Lange C, Ramasamy K, Mullin K, Menon R, Sampson AJ, Hsiao MY, Elliott KJ, Velicelebi G, Moscarillo T, Hyman BT, Wagner SL, Becker KD, Blacker D, Tanzi RE (2005). Family-based association between Alzheimer's disease and variants in UBQLN1. N Engl J Med 352:884–894. - PubMed
-
- Bird TD (2005). Genetic factors in Alzheimer's disease. N Engl J Med 352:862–864. - PubMed
-
- Blair CK, Folsom AR, Knopman DS, Bray MS, Mosley TH, Boerwinkle E (2005). APOE genotype and cognitive decline in a middle-aged cohort. Neurology 64:268–276. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous